Marimastat (BB2516): Current status of development

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 43, Issue , 1999, Pages

  Steward, William P ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

BB2516; Clinical development; Marimastat

Indexed keywords

MARIMASTAT;

ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; FATIGUE; HUMAN; LUNG SMALL CELL CANCER; MYALGIA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RASH; STOMACH CANCER; TENDINITIS;

EID: 0032983844     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051099     Document Type: Conference Paper

References (18)

1. Adams M, Thomas H (1998) A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer. Proc Am Soc Clin Oncol 17: 217a (abstract 838)
2. An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJP, Mountain A, Millican AT, Morphy R, Porter JR, Epemolu RO, Kubota T, Moossa AR, Hoffman RM (1997) Conversion of a highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis 15: 184
3. Anderson IC, Shipp MA, Docherty AJP, Teicher BA (1996) Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 56: 715
4. Beckett RP, Davidson AH, Drummond AH, Huxley P, Whittaker M (1996) Recent advances in matrix metalloproteinase inhibitor research. Drug Dev Today 1: 16
5. Brown PD (1997) Matrix metalloproteinases inhibitors in the treatment of cancer. Med Oncol 14: 1
6. Carmichael J, Ledermann J, Woll PJ, Gulliford T, Russell RC (1998) Phase IB study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer. Proc Am Soc Clin Oncol 17: 232a (abstract 888)
7. Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260
8. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM (1992) Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52: 701
9. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD (1996) Control of lymphatic and hematogenous metastases of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56: 2815
10. Giavazzi R, Garofalo A, Lucchini V, Bone EA, Chiari S, Brown PD, Nicoletti MI, Taraboletti G (1998) Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the anti-tumour activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 4: 985
11. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP (1997) Tissue inhibitors of metalloproteinases - structure, regulation and biological functions. Eur J Cell Biol 74: 111
12. Millar AW, Brown PD, Moore J, Galloway WA, Cornish AG, Lenehan TJ, Lynch KP (1998) Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 45: 21
13. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A (1998) Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumour markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4: 1101
14. Parsons SL, Watson SA, Griffin NR, Steele RJC (1996) An open phase I/II study of the oral matrix metalloproteinase inhibitor marimastat in patients with inoperable gastric cancer. Ann Oncol 7: 47
15. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, Miskin R (1988) Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 48: 3307
16. Santos O, McDermott CD, Daniels RG, Appelt K (1997) Rodent pharmacokinetic and antitumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin Exp Metastasis 15: 499
17. Sledge GW, Qulali M, Goulet R, Bone EA, Fife R (1995) Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546
18. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM (1994) Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54: 4726